Back to News
Market Impact: 0.2
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
Source: marketbeat.com
Healthcare & BiotechArtificial IntelligenceTechnology & Innovation
Compugen outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and said it is expanding its AI-powered discovery platform into tumor-associated antigen research. The update provides no clinical results, financial figures, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
CGEN0.25
More News
- World Bank warns of AI concentration risks as it lifts East Asia and Pacific growth outlook to 4.5%
- Security researcher claims to they found KVM guest-host escape flaw
- CH Robinson to Buy RXO for $5.8B in Bet on AI Model
- SpaceX stock climbs to highest since June, returning Musk to trillionaire status
- Schneider Electric drops $22.6B on PTC as datacenter boom rains money on infra companies
- Security researcher claims they found KVM guest-host escape flaw